miR-130 family-targeted LNA

miR-130 family-targeted LNA is an experimental antisense oligonucleotide therapy designed to inhibit the miR-130 family of microRNAs, which includes miR-130b, miR-301a, and miR-301b. Developed by researchers at Osaka University, this Locked Nucleic Acid (LNA) molecule is engineered to target a common seed sequence shared by these microRNAs. In bladder cancer, the miR-130 family is frequently upregulated and promotes malignant progression, including cell proliferation, migration, and invasion, by suppressing tumor suppressors such as Phosphatase and Tensin Homolog (PTEN) and Tyrosine-protein phosphatase non-receptor type 11 (PTPN11). By sequestering these microRNAs, the LNA restores the expression of PTEN and PTPN11, thereby inhibiting the activation of the FAK and Akt signaling pathways. Preclinical studies in murine xenograft models have demonstrated that this miR-130 family-targeted LNA can significantly suppress bladder tumor growth and motility.

Other names

miR-130 family seed-targeting locked nucleic acidmiR130 family seed-targeting locked nucleic acidmiR 130 family seed-targeting locked nucleic acid